Transatlantic Comparative Perspectives on Patenting Genome-editing Technologies: A Case Study of Patents on CRISPR/Cas9 Technology

Juli Mansnerus, Liisa Vaaraniemi

Tutkimustuotos: Artikkeli kirjassa/raportissa/konferenssijulkaisussaKirjan luku tai artikkeliTieteellinenvertaisarvioitu

Abstrakti

This chapter investigates the patentability of CRISPR/Cas9 technology in Europe and the United States. Special attention is paid to the recent legal dispute over a patent concerning the use of the CRISPR/Cas9 system in eukaryotic cells. The parties involved in the dispute are two academic institutions, the University of California (the ‘UC’) and the Broad Institute of MIT and Harvard (the ‘Broad Institute’), which have been investigating the system and its potential use as a genome-editing tool. Interestingly, the United States Patent and Trademark Office (the ‘USPTO’) and the European Patent Office (the ‘EPO’) have granted the patent to both of the parties of the legal dispute. In particular, the two patent offices have adopted a very different approach to the concepts of innovative step and obviousness in inventions. This dispute influences the scientific community and those who wish to use this technology commercially. This chapter will look in more detail into the implications of this legal dispute as well as some lessons learned
Alkuperäiskielienglanti
OtsikkoPersonalized Medicine : Legal and Ethical Challenges
ToimittajatJuli Mansnerus, Raimo Lahti, Amanda Blick
Sivumäärä27
JulkaisupaikkaHelsinki
KustantajaUniversity of Helsinki, Faculty of Law
Julkaisupäivä2020
Sivut187-214
ISBN (painettu)978-951-51-6940-2
ISBN (elektroninen)978-951-51-6941-9
DOI - pysyväislinkit
TilaJulkaistu - 2020
OKM-julkaisutyyppiA3 Kirjan tai muun kokoomateoksen osa

Julkaisusarja

NimiForum Iuris
ISSN (painettu)1456-842X
ISSN (elektroninen)2342-8996

Tieteenalat

  • 513 Oikeustiede

Siteeraa tätä